Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482901 | 0.86 | LMNA (0.64) | KMT2ALMNAHPGDMEN1RAB9A | |
| SCHEMBL14273740 | 0.84 | HPGD (0.60) | KMT2ALMNAHPGDMEN1RAB9A | |
| SCHEMBL21178388 | 0.83 | PTPRZ1 (0.46) | KMT2ALMNAHPGDMEN1RAB9A | |
| SCHEMBL17298901 | 0.80 | LMNA (0.44) | KMT2ALMNASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL13932527 | 0.78 | KMT2A (0.83) | KMT2ALMNAHPGDMEN1RAB9A | |
| SCHEMBL13255794 | 0.78 | HPGD (0.69) | KMT2ALMNAHPGDMEN1RAB9A | |
| SCHEMBL15610864 | 0.78 | KMT2A (0.54) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21391252 | 0.77 | HPGD (0.83) | KMT2ALMNAHPGDMEN1RAB9A | |
| SCHEMBL934891 | 0.76 | AOC2 (0.64) | KMT2ALMNAHPGDMEN1RAB9A | |
| SCHEMBL12471200 | 0.76 | TRPV1 (0.48) | KMT2ALMNAMEN1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | KMT2A 1713/4885LMNA 2451/4885HPGD 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.